Format

Send to

Choose Destination
See comment in PubMed Commons below
Pak J Med Sci. 2014 May;30(3):539-44. doi: 10.12669/pjms.303.4773.

Acetylsalicylic Acid resistance in patients with type 2 diabetes mellitus, prediabetes & non-diabetic coronary artery disease.

Author information

  • 1Mustafa Cetin, MD, Department of Cardiology, Ankara Numune Education and Research Hospital, Talatpasa Bulvari, 06100, Sihhiye, Ankara, Turkey.
  • 2Emrullah Kiziltunc, MD, Department of Cardiology, Ankara Numune Education and Research Hospital, Talatpasa Bulvari, 06100, Sihhiye, Ankara, Turkey.
  • 3Zehra Guven Cetin, MD, Department of Cardiology, Ankara Numune Education and Research Hospital, Talatpasa Bulvari, 06100, Sihhiye, Ankara, Turkey.
  • 4Hulya Cicekcioglu, MD, Department of Cardiology, Ankara Numune Education and Research Hospital, Talatpasa Bulvari, 06100, Sihhiye, Ankara, Turkey.
  • 5Muslum Sahin MD, Department of Cardiology, Ankara Numune Education and Research Hospital, Talatpasa Bulvari, 06100, Sihhiye, Ankara, Turkey.
  • 6Serhat Isik, MD, Department of Endocrinology and Metabolism, Ankara Numune Education and Research Hospital, Talatpasa Bulvari, 06100, Sihhiye, Ankara, Turkey.
  • 7Alparslan Kurtul, MD, Department of Cardiology, Ankara Education and Research Hospital, Sukriye Mahallesi, Ulucanlar Caddesi, 06340, Ankara, Turkey.
  • 8Ender Ornek, Associate Professor, Department of Cardiology, Ankara Numune Education and Research Hospital, Talatpasa Bulvari, 06100, Sihhiye, Ankara, Turkey.
  • 9Feridun Vasfi Ulusoy, MD, Department of Cardiology, Ankara Numune Education and Research Hospital, Talatpasa Bulvari, 06100, Sihhiye, Ankara, Turkey.

Abstract

Objective : Several studies have demonstrated the beneficial role of antiplatelet therapy with acetylsalicylic acid (ASA) at atherosclerotic vascular disease. Antiaggregant effect of ASA is not uniform in all patients. Purpose of the present study is to evaluate the prevalence of ASA resistance in patients with type 2 diabetes mellitus (T2DM), pre-diabetes and non-diabetic coronary artery disease (CAD).

METHODS:

Effect of ASA was assessed using the platelet function analyzer (PFA-100) system. Resistance to ASA was defined as a normal collagen/epinephrine induced closure time after one week of ASA therapy. Patients with non-diabetic CAD, pre-diabetes and T2DM were compared.

RESULTS:

ASA resistance was found in 26 (37.1%), 6 (17.6%) and 41 (26.5%) patients in the groups, respectively (p=0.154). ASA resistance was found to be significantly higher in men, smokers and insulin users, besides this it was found to be significantly lower in beta blocker (BB) users, angiotensin converting enzyme inhibitor (ACEI) users with univariate analysis. However insulin usage was found to be the single effective parameter on ASA resistance in multivariate analysis.

CONCLUSION:

There was no difference with regard to ASA resistance between groups. While ASA resistance was higher in men, smokers and insulin users, it was lower in patients using BBs and ACEIs.

KEYWORDS:

Acetylsalicylic acid resistance; Coronary artery disease; Diabetes mellitus

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk